LYEL

Company Overview — What Does Lyell Immunopharma, Inc. Do?

Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California. Lyell Immunopharma, Inc. (LYEL) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Elizabeth Homans and employs approximately 270 people. With a market capitalization of $485M, LYEL is one of the notable companies in the Healthcare sector.

Lyell Immunopharma, Inc. (LYEL) Stock Rating — Reduce (April 2026)

As of April 2026, Lyell Immunopharma, Inc. receives a Reduce rating with a composite score of 31.1/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.LYEL ranks #3,297 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Lyell Immunopharma, Inc. ranks #500 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

LYEL Stock Price and 52-Week Range

Lyell Immunopharma, Inc. (LYEL) currently trades at $22.39. The stock lost $1.46 (6.1%) in the most recent trading session. The 52-week high for LYEL is $45.00, which means the stock is currently trading -50.2% from its annual peak. The 52-week low is $0.39, putting the stock 5641.0% above its annual trough. Recent trading volume was 108K shares, suggesting relatively thin trading activity.

Is LYEL Overvalued or Undervalued? — Valuation Analysis

Lyell Immunopharma, Inc. (LYEL) carries a value factor score of 13/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 2.05x, versus the sector average of 2.75x. The price-to-sales ratio is 7938.94x, compared to 1.66x for the average Healthcare stock.

At current multiples, Lyell Immunopharma, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Lyell Immunopharma, Inc. Profitability — ROE, Margins, and Quality Score

Lyell Immunopharma, Inc. (LYEL) earns a quality factor score of 23/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -71.8%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -52.4% versus the sector average of -33.1%.

On a margin basis, Lyell Immunopharma, Inc. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -451419.0% (sector: -66.1%). Net profit margin stands at -417323.2%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 15.4% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

LYEL Debt, Balance Sheet, and Financial Health

Lyell Immunopharma, Inc. has a debt-to-equity ratio of 37.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 5.28x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $124M.

LYEL has a beta of 3.66, meaning it is more volatile than the broader market — a $10,000 investment in LYEL would be expected to move 265.9% more than the S&P 500 on any given day. The stability factor score for Lyell Immunopharma, Inc. is 10/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Lyell Immunopharma, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Lyell Immunopharma, Inc. reported revenue of $64,000 and earnings per share (EPS) of $-16.06. Net income for the quarter was $-178M. Gross margin was 100.0%. Operating income came in at $-192M.

In FY 2025, Lyell Immunopharma, Inc. reported revenue of $36,000 and earnings per share (EPS) of $-16.06. Net income for the quarter was $-274M. Revenue grew -41.0% year-over-year compared to FY 2024. Operating income came in at $-269M.

In Q3 2025, Lyell Immunopharma, Inc. reported revenue of $15,000 and earnings per share (EPS) of $-2.13. Net income for the quarter was $-39M. Revenue grew -55.9% year-over-year compared to Q3 2024. Operating income came in at $-37M.

In Q2 2025, Lyell Immunopharma, Inc. reported revenue of $8,000 and earnings per share (EPS) of $-2.89. Net income for the quarter was $-43M. Revenue grew -38.5% year-over-year compared to Q2 2024. Operating income came in at $-47M.

Over the past 8 quarters, Lyell Immunopharma, Inc. has demonstrated a growth trajectory, with revenue expanding from $13,000 to $64,000. Investors analyzing LYEL stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

LYEL Dividend Yield and Income Analysis

Lyell Immunopharma, Inc. (LYEL) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

LYEL Momentum and Technical Analysis Profile

Lyell Immunopharma, Inc. (LYEL) has a momentum factor score of 64/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 27/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 27/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

LYEL vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Lyell Immunopharma, Inc. (LYEL) ranks #500 out of 838 stocks based on the Blank Capital composite score. This places LYEL in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing LYEL against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full LYEL vs S&P 500 (SPY) comparison to assess how Lyell Immunopharma, Inc. stacks up against the broader market across all factor dimensions.

LYEL Next Earnings Date

No upcoming earnings date has been announced for Lyell Immunopharma, Inc. (LYEL) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy LYEL? — Investment Thesis Summary

The quantitative profile for Lyell Immunopharma, Inc. suggests caution. The quality score of 23/100 flags below-average profitability. The value score of 13/100 indicates premium valuation. Price momentum is positive at 64/100, suggesting the trend favors buyers. High volatility (stability score 10/100) increases portfolio risk.

In summary, Lyell Immunopharma, Inc. (LYEL) earns a Reduce rating with a composite score of 31.1/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on LYEL stock.

Related Resources for LYEL Investors

Explore more research and tools: LYEL vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare LYEL head-to-head with peers: LYEL vs AZN, LYEL vs SLGL, LYEL vs VMD.